Eric W. Kimble
Director/Board Member chez National Psoriasis Foundation, Inc.
Profil
Eric W.
Kimble currently works at National Psoriasis Foundation, Inc., as Trustee from 2009.
Mr. Kimble also formerly worked at Biogen, Inc., as Marketing Director-US Immunology Franchise in 2004, Merck & Co., Inc., as Product Manager in 1999, Cubist Pharmaceuticals LLC, as Vice President-Sales, Arthur D.
Little, Inc., as Research Associate, Entasis Therapeutics, Inc., as Chief Commercial Officer from 2019 to 2020, Entasis Therapeutics Holdings, Inc., as Chief Commercial Officer from 2019 to 2020, and Invivyd, Inc., as Chief Commercial Officer from 2020 to 2022.
Mr. Kimble received his undergraduate degree from Brown University and Masters Business Admin degree from Harvard Business School.
Postes actifs de Eric W. Kimble
| Sociétés | Poste | Début |
|---|---|---|
National Psoriasis Foundation, Inc.
 National Psoriasis Foundation, Inc. Investment Trusts/Mutual FundsMiscellaneous The National Psoriasis Foundation is a non-profit organization that aims to provide assistance to individuals suffering from psoriasis and psoriatic arthritis. The private company is based in Portland, OR. The company strives to help patients get the necessary treatment while also promoting research to find a cure for these conditions. | Director/Board Member | 28/05/2010 |
Anciens postes connus de Eric W. Kimble
| Sociétés | Poste | Fin |
|---|---|---|
| INVIVYD, INC. | Corporate Officer/Principal | 13/10/2022 |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | 04/09/2020 |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Corporate Officer/Principal | 01/09/2020 |
| BIOGEN INC. | Sales & Marketing | 01/01/2004 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/1999 |
Formation de Eric W. Kimble
| Brown University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| BIOGEN INC. | Health Technology |
| INVIVYD, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Arthur D. Little, Inc.
 Arthur D. Little, Inc. Miscellaneous Commercial ServicesCommercial Services Arthur D. Little, Inc. engages in the provision of management consulting services. It specializes in strategy and organization, operations management, technology and innovation management, corporate finance, and global carbon advisory serving corporations and organizations worldwide. The firm serves the automotive, healthcare, information, chemicals, consumer goods, retail, manufacturing, and transportation industries. The company was founded by Arthur Dehon Little and Roger Griffin in October 1886 and is headquartered in Boston, MA. | Commercial Services |
National Psoriasis Foundation, Inc.
National Psoriasis Foundation, Inc. Investment Trusts/Mutual FundsMiscellaneous The National Psoriasis Foundation is a non-profit organization that aims to provide assistance to individuals suffering from psoriasis and psoriatic arthritis. The private company is based in Portland, OR. The company strives to help patients get the necessary treatment while also promoting research to find a cure for these conditions. | Miscellaneous |
Entasis Therapeutics, Inc.
Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Health Technology |
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
